Drugs / WS016
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06281470 | Feb → Jun 2023 | — | Waterstone Pharmaceutical (Wuhan) Co., LTD. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06277128 | Sep 2023 → Apr 2024 | — | Waterstone Pharmaceutical (Wuhan) Co., LTD. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07251309 | Dec 2024 → Nov 2026 expected | — | Waterstone Pharmaceutical (Wuhan) Co., LTD. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-08-25 | Waterstone Pharmaceutical (Wuhan) Co., LTD. | Results 中美华世通宣布WS016在Ⅲ期临床试验中取得积极顶线数据 waterstonepharma.com ↗
WS016 干混悬剂在中国开展的治疗成人高钾血症的关键Ⅲ期临床试验取得积极顶线结果，计划于近期向国家药品监督管理局（NMPA）递交WS016高钾血适应症的新药上市申请（NDA）。 |
| 2023-02-27 | Waterstone Pharmaceutical (Wuhan) Co., LTD. | Regulatory 中美华世通：国内首个降血钾高分子创新药WS016干混悬剂获批开展临床 waterstonepharma.com ↗
2022年12月14日，CDE官网显示，中美华世通生物医药科技（武汉）股份有限公司（以下称“中美华世通”）自主开发的1类新药WS016干混悬剂获批临床，未来将开展针对高钾血症的临床研究。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-08-25 | Waterstone Pharmaceutical (Wuhan) Co., LTD. | 中美华世通宣布WS016在Ⅲ期临床试验中取得积极顶线数据 waterstonepharma.com ↗ |
| 2023-02-27 | Waterstone Pharmaceutical (Wuhan) Co., LTD. | 中美华世通：国内首个降血钾高分子创新药WS016干混悬剂获批开展临床 waterstonepharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WS016 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06277128 ↗ |
| Route | Oral | “WS016, oral” NCT06277128 ↗ |